BioNTech SE (BNTX) Q3 2026 Earnings Report

The call was broadly optimistic, supported by strong gotistobart survival data, encouraging pumitamig combination results, a growing late-stage pipeline, a substantial cash balance, and a raised revenue-guidance midpoint. However, the company also reported lower COVID-19-related revenue, higher R&D and SG&A expenses, discontinuation of the colorectal cancer trial, a missed progression-free survival endpoint for BNT113, and limitations and safety concerns around T-Pam. The highlights significantly outweighed the lowlights, although several clinical programs remain subject to upcoming readouts and development decisions.

BioNTech raised its full year 2026 revenue guidance to EUR 1.7 billion to EUR 1.9 billion, while maintaining adjusted R&D expense guidance of EUR 2 billion to EUR 2.3 billion and adjusted SG&A expense guidance of EUR 700 million to EUR 800 million; it expects the first interim analysis for gotistobart in squamous non-small cell lung cancer before year-end, a second one next year, first trials for pumitamig and Alpha-D novel combinations to begin in 2027, first-line TNBC in China data in 2027, ROSETTA Lung-02 and ROSETTA Lung-01 around 2029, and readouts for RCC, CRC, HCC, and the other studies thereafter, while it has seven global pivotal studies ongoing by end of this year and remains on track to become a diversified multi-product company by 2030.